Stay updated with breaking news from Pharma Corp. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) ("CTI"), a commercial biopharmaceutical company focused on the development and commercialization of novel...
SEATTLE, May 30, 2023 /PRNewswire/ -- CTI BioPharma Corp. , a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-related... | June 7, 2023
A number of firms have modified their ratings and price targets on shares of CTI BioPharma (NASDAQ: CTIC) recently: 5/15/2023 – CTI BioPharma was downgraded by analysts at Stifel Nicolaus from a “buy” rating to a “hold” rating. 5/11/2023 – CTI BioPharma was downgraded by analysts at JMP Securities from an “outperform” rating to a […]
NEW YORK, May 13, 2023 (GLOBE NEWSWIRE) -- CTI BioPharma Corp (NASDAQ: CTIC) Lifshitz Law PLLC announces an investigation into possible breach...
Transaction Price of $9.10 Per Share Represents Compelling 89% Premium to CTI's Closing Stock Price on May 9, 2023 SEATTLE, May 10, 2023 /PRNewswire/ -- CTI BioPharma , a commercial... | May 10, 2023